Healthcare Tips

Insomnia - Ramelteon demonstrates no abuse potential according to study results

April 29, 2019

Results of a clinical study indicated that ramelteon, an investigational compound currently under review by the FDA for insomnia treatment, had no more potential for abuse than placebo in individuals with a history of polydrug abuse. These results, presented at the 2005 American Psychiatric Association Annual Meeting, showed that patients exhibited no abuse potential or behavioral impairment at up to 20 times the proposed therapeutic dose of ramelteon compared to placebo.

"In the treatment of insomnia, drug abuse potential is a significant concern to patients as well as to prescribing physicians," said Roland Griffiths, PhD, Professor in the departments of Psychiatry and Neuroscience, Johns Hopkins Bayview Medical Center, Baltimore, MD. "The chronic nature of some types of insomnia may necessitate treatment for an extended period, underscoring the need for sleep medications with little or no abuse potential."

It is estimated that 60 million Americans suffer from insomnia at least a few nights per week. Most currently prescribed sleep agents and some investigational drugs work by targeting gamma-aminobutyric acid (GABA) receptors, which are located throughout the brain. In pre-clinical studies, ramelteon has shown no affinity for GABA or opiate receptors.

Study Design

This study was a placebo-controlled, crossover clinical study of fourteen adults with a history of polydrug or multiple-drug abuse. These subjects were entered into a 7-day double-blind treatment period, comparing behavioral effects and abuse potential of ramelteon and triazolam, a benzodiazepine sedative-hypnotic.

During the treatment period, study medication was administered to patients in a randomly-assigned sequence and included:

-- ramelteon (16 mg, 80 mg, 160 mg);

-- triazolam (0.25 mg, 0.50 mg, 0.75 mg); and,

-- placebo.

Measures of "drug-liking," were assessed each day using questionnaires completed at intervals between 0.5 hours pre-dose, up to 24 hours after dose administration. Memory, reaction time and standing balance tasks were also performed at each of these time intervals. Analysis of peak drug-liking scores showed a dose-response effect in patients receiving triazolam, with significantly greater peak liking reported at the higher doses (0.50 mg, 0.75 mg) as compared with placebo (p